• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mundipharma - Articles and news items

First biosimilar mAb in oncology granted EU approval

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union (EU)…

Mundipharma announces EU regulatory submission for Nyxoid

Industry news / 4 November 2016 / Niamh Louise Marriott, Digital Content Producer

Studies showed that Nyxoid is bioequivalent to injectable naloxone as a first line treatment for opioid overdose, with an intranasal 1.8 mg dose…

First-in-human trial of MundiPharma’s EDO-S101 starts

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances…

Mundipharma obtains global ex-US rights to Zubsolv

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence…

Real world study demonstrates effectiveness of biosimilar infliximab

Industry news / 6 January 2016 / Victoria White

Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab…

FDA accepts Mundipharma EDO’s IND for EDO-S101

Industry news / 3 August 2015 / Victoria White

The FDA has accepted Mundipharma EDO’s IND for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours…


Mundipharma donates BETADINE to support the fight against Ebola in West Africa

Industry news / 17 February 2015 / Mundipharma

Mundipharma to provide supplies for at least two million handwashes in Ebola treatment centres…

Mundipharma receives positive EC decision on Targin® (oxycodone / naloxone) for Restless Legs Syndrome

Industry news / 7 January 2015 / Mundipharma

Mundipharma announced that Targin® (Targinact®, Targiniq®), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for a new indication, as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy…

Mundipharma calls for broader stakeholder consensus on pain trial endpoints to meet payer’s requirements

Industry news / 11 November 2014 / Mundipharma

New research unveiled by Mundipharma highlights inconsistencies in health economic models and measurement methods used in clinical trials for pain therapies…

Mundipharma announces results of pivotal phase III study for flutiform® in paediatric asthma

Industry news / 8 September 2014 / Mundipharma

New data from a randomised, multicentre, phase III study, being presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, supports the potential of flutiform® for the treatment of paediatric asthma…